Kyverna Therapeutics

KYTX

Market cap $474M

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and eliminated immunotherapy dependence, with a favorable safety profile and no high-grade CRS or ICANS events. A BLA submission for SPS is targeted for 1H26, with FDA approval prospects strengthened by RMAT and Orphan Drug designations.

Kyverna Therapeutics said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending its shares surging 20% in premarket trading.

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – – Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –

In November, Seeking Alpha welcomed 24 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The Academic Investor, recommending Galaxy Digital; Richard Doxtator, presenting on Moonlake Immunotherapeutics; and ML Research, writing about Sezzle—all rated Strong Buys. Analysts' diverse interests range from technology (AI, in particular) to digital assets to EM equities, with investment strategies focusing on value and growth investing.

Kyverna Therapeutics receives a strong buy rating with a $55 price target, driven by revolutionary Phase 2 data for KYV-101 in myasthenia gravis. KYV-101 demonstrated double the efficacy of standard care and enabled 100% of patients to achieve drug-free remission, with a best-in-class safety profile. The platform is significantly de-risked, with experienced management, strong financials, and clear near-term catalysts, including SPS BLA filing and a pivotal Phase 3 trial.

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026

EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17, 2025 at 1:00 p.m.

Initial funding of $25 million from the first of four tranches  Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities Topline data readout of registrational Phase 2 SPS trial now expected in early 2026; narrowed from previous guidance of first half 2026 EMERYVILLE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that, on October 31, 2025, it closed a loan facility with Oxford Finance LLC ("Oxford Finance") for up to $150 million in non-dilutive capital.

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial